Azilect and Breastfeeding
Based on information obtained from animal studies on Azilect (rasagiline mesylate) and breastfeeding, the medication is believed to negatively affect a woman's ability to breastfeed successfully. Studies in rats suggest that the drug may lower prolactin levels, a hormone that is important for breastfeeding. If you are taking Azilect and breastfeeding, ask your healthcare provider about any potential risks.
It is unknown whether Azilect® (rasagiline mesylate) passes through breast milk in humans. Theoretically, the medication could interfere with a woman's ability to breastfeed. Therefore, you should talk with your healthcare provider before taking Azilect if you are breastfeeding or plan to start.
No studies have been conducted on whether Azilect passes through breast milk. Studies in rats suggest that the drug can lower prolactin levels. Prolactin is a hormone that is important for breastfeeding. As a result, Azilect may negatively affect a woman's ability to breastfeed successfully.
You should talk with your healthcare provider about Azilect and breastfeeding. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision about Azilect and breastfeeding that is right for you.